术中地塞米松对婴儿心脏手术后主要并发症和死亡率的影响:DECISION随机临床试验
DECISION试验为研究者发起的双盲多中心随机对照试验,纳入中国、巴西和俄罗斯4个中心共394例12个月以下接受体外循环心脏手术的婴儿,地塞米松组(n=194)麻醉诱导后静脉给予地塞米松1 mg/kg,对照组(n=200)给予等体积0.9%氯化钠。主要终点为术后30天内死亡、非致死性心肌梗死、需体外膜肺氧合、需心肺复苏、急性肾损伤、延长机械通气或神经系统并发症的复合终点,地塞米松组发生74例(38.1%)vs 对照组91例(45.5%),绝对风险降低7.4%(95%CI -0.8%至15.3%),风险比0.82(95%CI 0.60至1.10),P=0.20。17个预设次要终点均无统计学显著差异,感染发生在地塞米松组4例(2.0%)vs 对照组3例(1.5%)。作者结论认为术中地塞米松未显著减少30天主要并发症和死亡,但研究可能把握度不足。
要点
- 12个月以下体外循环心脏手术婴儿,麻醉诱导后静脉地塞米松1 mg/kg vs 等体积0.9%氯化钠,30天主要复合终点38.1% vs 45.5%,HR 0.82(95%CI 0.60-1.10),P=0.20,未达统计学显著。
- 绝对风险降低7.4%(95%CI -0.8%至15.3%),置信区间下限跨0,不能排除无效。
- 17个预设次要终点均无统计学显著差异。
- 感染发生在地塞米松组4例(2.0%)vs 对照组3例(1.5%)。
- 作者结论认为该研究可能把握度不足,未能检出具有临床意义的差异。
适用人群与场景
- 12个月以下接受体外循环心脏手术的婴儿,来自中国、巴西和俄罗斯4个中心,2015年12月至2018年10月入组,随访至2018年11月完成。
处置流程与药物剂量
- 地塞米松组(n=194)在麻醉诱导后静脉给予地塞米松1 mg/kg。
- 对照组(n=200)在麻醉诱导后静脉给予等体积0.9%氯化钠。
研究设计与关键结果
- 研究类型:研究者发起的双盲多中心随机对照试验,4个中心,纳入394例12个月以下体外循环心脏手术婴儿,地塞米松组194例 vs 对照组200例,全部完成试验。
- 主要终点(术后30天内死亡、非致死性心肌梗死、需体外膜肺氧合、需心肺复苏、急性肾损伤、延长机械通气或神经系统并发症的复合终点):地塞米松组74例(38.1%)vs 对照组91例(45.5%),绝对风险降低7.4%(95%CI -0.8%至15.3%),HR 0.82(95%CI 0.60至1.10),P=0.20。
- 17个预设次要终点均无统计学显著差异。
- 感染:地塞米松组4例(2.0%)vs 对照组3例(1.5%)。
证据类型、等级与局限
- 证据类型:双盲多中心随机对照试验。
- 局限:作者指出研究可能把握度不足,未能检出具有临床意义的差异。
对床旁实践的改变
- 作者结论认为,在12个月以下接受体外循环心脏手术的婴儿中,术中给予地塞米松与安慰剂相比未显著减少30天主要并发症和死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Corticosteroids are widely used in pediatric cardiac surgery to blunt systemic inflammatory response and to reduce complications; nevertheless, their clinical efficacy is uncertain.
OBJECTIVE: To determine whether intraoperative administration of dexamethasone is more effective than placebo for reducing major complications and mortality during pediatric cardiac surgery.
DESIGN, SETTING, AND PARTICIPANTS: The Intraoperative Dexamethasone in Pediatric Cardiac Surgery was an investigator-initiated, double-blind, multicenter randomized trial that involved 4 centers in China, Brazil, and Russia. A total of 394 infants younger than 12 months, undergoing cardiac surgery with cardiopulmonary bypass were enrolled from December 2015 to October 2018, with follow-up completed in November 2018.
INTERVENTIONS: The dexamethasone group (n = 194) received 1 mg/kg of dexamethasone; the control group (n = 200) received an equivolume of 0.9% sodium chloride intravenously after anesthesia induction.
MAIN OUTCOMES AND MEASURES: The primary end point was a composite of death, nonfatal myocardial infarction, need for extracorporeal membrane oxygenation, need for cardiopulmonary resuscitation, acute kidney injury, prolonged mechanical ventilation, or neurological complications within 30 days after surgery. There were 17 secondary end points, including the individual components of the primary end point, and duration of mechanical ventilation, inotropic index, intensive care unit stay, readmission to intensive care unit, and length of hospitalization.
RESULTS: All of the 394 patients randomized (median age, 6 months; 47.2% boys) completed the trial. The primary end point occurred in 74 patients (38.1%) in the dexamethasone group vs 91 patients (45.5%) in the control group (absolute risk reduction, 7.4%; 95% CI, -0.8% to 15.3%; hazard ratio, 0.82; 95% CI, 0.60 to 1.10; P = .20). Of the 17 prespecified secondary end points, none showed a statistically significant difference between groups. Infections occurred in 4 patients (2.0%) in the dexamethasone group vs 3 patients (1.5%) in the control group.
CONCLUSIONS AND RELEVANCE: Among infants younger than 12 months undergoing cardiac surgery with cardiopulmonary bypass, intraoperative administration of dexamethasone, compared with placebo, did not significantly reduce major complications and mortality at 30 days. However, the study may have been underpowered to detect a clinically important difference.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02615262.
参考来源
- Lomivorotov V, Kornilov I, Boboshko V, et al. Effect of Intraoperative Dexamethasone on Major Complications and Mortality Among Infants Undergoing Cardiac Surgery: The DECISION Randomized Clinical Trial. JAMA. 2020. PMID: 32573670. doi:10.1001/jama.2020.8133
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。